Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.500
-0.100 (-6.25%)
At close: Sep 26, 2025, 4:00 PM EDT
1.510
+0.010 (0.67%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Aptevo Therapeutics Employees
Aptevo Therapeutics had 37 employees as of December 31, 2024. The number of employees decreased by 3 or -7.50% compared to the previous year.
Employees
37
Change (1Y)
-3
Growth (1Y)
-7.50%
Revenue / Employee
n/a
Profits / Employee
-$649,324
Market Cap
4.93M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
APVO News
- 11 days ago - Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML - Accesswire
- 23 days ago - Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules - Accesswire
- 6 weeks ago - Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer - Accesswire
- 6 weeks ago - Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update - Accesswire
- 3 months ago - Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 3 months ago - Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers - Accesswire
- 3 months ago - Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
- 3 months ago - Aptevo More Than Doubles After Favorable Results in Leukemia Study - Market Watch